Thermo Fisher Scientific Inc. operates in 4 segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Price to Earnings (P/E) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Segment Profit Margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | Life Sciences Solutions | Life Sciences Solutions segment profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Analytical Instruments | Analytical Instruments segment profit margin ratio improved from 2021 to 2022 and from 2022 to 2023. | |
Specialty Diagnostics | Specialty Diagnostics segment profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 exceeding 2021 level. | |
Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment profit margin ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Profit Margin: Life Sciences Solutions
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Revenues | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment profit margin = 100 × Segment income ÷ Revenues
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | Life Sciences Solutions | Life Sciences Solutions segment profit margin ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Profit Margin: Analytical Instruments
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Revenues | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment profit margin = 100 × Segment income ÷ Revenues
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | Analytical Instruments | Analytical Instruments segment profit margin ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Profit Margin: Specialty Diagnostics
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Revenues | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment profit margin = 100 × Segment income ÷ Revenues
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | Specialty Diagnostics | Specialty Diagnostics segment profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 exceeding 2021 level. |
Segment Profit Margin: Laboratory Products and Biopharma Services
Thermo Fisher Scientific Inc.; Laboratory Products and Biopharma Services; segment profit margin calculation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Revenues | |||||
Segment Profitability Ratio | |||||
Segment profit margin1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment profit margin = 100 × Segment income ÷ Revenues
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment profit margin | Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment profit margin ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Return on Assets (Segment ROA)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | Life Sciences Solutions | Life Sciences Solutions segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Analytical Instruments | Analytical Instruments segment ROA improved from 2021 to 2022 and from 2022 to 2023. | |
Specialty Diagnostics | Specialty Diagnostics segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. | |
Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment ROA improved from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: Life Sciences Solutions
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment ROA = 100 × Segment income ÷ Total assets
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | Life Sciences Solutions | Life Sciences Solutions segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: Analytical Instruments
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment ROA = 100 × Segment income ÷ Total assets
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | Analytical Instruments | Analytical Instruments segment ROA improved from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: Specialty Diagnostics
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment ROA = 100 × Segment income ÷ Total assets
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | Specialty Diagnostics | Specialty Diagnostics segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: Laboratory Products and Biopharma Services
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Segment income | |||||
Total assets | |||||
Segment Profitability Ratio | |||||
Segment ROA1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment ROA = 100 × Segment income ÷ Total assets
= 100 × ÷ =
Segment profitability ratio | Reportable segment | The company |
---|---|---|
Segment ROA | Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment ROA improved from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | Life Sciences Solutions | Life Sciences Solutions segment asset turnover ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Analytical Instruments | Analytical Instruments segment asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023. | |
Specialty Diagnostics | Specialty Diagnostics segment asset turnover ratio deteriorated from 2021 to 2022 and from 2022 to 2023. | |
Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover: Life Sciences Solutions
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment asset turnover = Revenues ÷ Total assets
= ÷ =
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | Life Sciences Solutions | Life Sciences Solutions segment asset turnover ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover: Analytical Instruments
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment asset turnover = Revenues ÷ Total assets
= ÷ =
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | Analytical Instruments | Analytical Instruments segment asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover: Specialty Diagnostics
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment asset turnover = Revenues ÷ Total assets
= ÷ =
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | Specialty Diagnostics | Specialty Diagnostics segment asset turnover ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover: Laboratory Products and Biopharma Services
Thermo Fisher Scientific Inc.; Laboratory Products and Biopharma Services; segment asset turnover calculation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Revenues | |||||
Total assets | |||||
Segment Activity Ratio | |||||
Segment asset turnover1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment asset turnover = Revenues ÷ Total assets
= ÷ =
Segment activity ratio | Reportable segment | The company |
---|---|---|
Segment asset turnover | Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023. |
Segment Capital Expenditures to Depreciation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | Life Sciences Solutions | Life Sciences Solutions segment capital expenditures to depreciation ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Analytical Instruments | Analytical Instruments segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. | |
Specialty Diagnostics | Specialty Diagnostics segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. | |
Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment capital expenditures to depreciation ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Capital Expenditures to Depreciation: Life Sciences Solutions
Thermo Fisher Scientific Inc.; Life Sciences Solutions; segment capital expenditures to depreciation calculation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Capital expenditures | |||||
Depreciation | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment capital expenditures to depreciation = Capital expenditures ÷ Depreciation
= ÷ =
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | Life Sciences Solutions | Life Sciences Solutions segment capital expenditures to depreciation ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Capital Expenditures to Depreciation: Analytical Instruments
Thermo Fisher Scientific Inc.; Analytical Instruments; segment capital expenditures to depreciation calculation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Capital expenditures | |||||
Depreciation | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment capital expenditures to depreciation = Capital expenditures ÷ Depreciation
= ÷ =
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | Analytical Instruments | Analytical Instruments segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Capital Expenditures to Depreciation: Specialty Diagnostics
Thermo Fisher Scientific Inc.; Specialty Diagnostics; segment capital expenditures to depreciation calculation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Capital expenditures | |||||
Depreciation | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment capital expenditures to depreciation = Capital expenditures ÷ Depreciation
= ÷ =
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | Specialty Diagnostics | Specialty Diagnostics segment capital expenditures to depreciation ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. |
Segment Capital Expenditures to Depreciation: Laboratory Products and Biopharma Services
Thermo Fisher Scientific Inc.; Laboratory Products and Biopharma Services; segment capital expenditures to depreciation calculation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||
Capital expenditures | |||||
Depreciation | |||||
Segment Financial Ratio | |||||
Segment capital expenditures to depreciation1 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Segment capital expenditures to depreciation = Capital expenditures ÷ Depreciation
= ÷ =
Segment financial ratio | Reportable segment | The company |
---|---|---|
Segment capital expenditures to depreciation | Laboratory Products and Biopharma Services | Laboratory Products and Biopharma Services segment capital expenditures to depreciation ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Revenues
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services | |||||
Eliminations | |||||
Consolidated |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Segment income
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services | |||||
Consolidated |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Depreciation
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services | |||||
Consolidated |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Total assets
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services | |||||
Corporate/other | |||||
Consolidated |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Capital expenditures
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
---|---|---|---|---|---|
Life Sciences Solutions | |||||
Analytical Instruments | |||||
Specialty Diagnostics | |||||
Laboratory Products and Biopharma Services | |||||
Corporate/other | |||||
Consolidated |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).